Q3 2024 Avantor Inc Earnings Call
Good morning, My name is M&A and I'll be your conference operator today.
At this time I would like to welcome everyone to evolve towards that of course that 'twenty 'twenty four earnings results conference call.
After the prepared remarks, there will be the opportunity for you to ask any questions, which you can do so by pressing star followed by the number one on your telephone keypad.
Speaker Change: I'll now turn the call over to Christina James Vice President of Investor Relations Ms. James You May begin the conference. Good morning. Thank you for joining us our speakers today are Michael Stubblefield, President and Chief Executive Officer, and Brent Jones, Executive Vice President and Chief Financial Officer.
Christina James: Press release and the presentation accompanying this call are available on our Investor Relations website at IR Dot of Entre Sciences dotcom.
Christina James: A replay of this webcast will also be made available on our website after the call.
Christina James: Following our prepared remarks, we will open the line for questions.
Christina James: During this call we will be making forward looking statements within the meaning of the U S. Federal securities laws, including statements regarding events or developments that we believe or anticipate may occur in the future.
Christina James: These forward looking statements are subject to a number of risks and uncertainties, including those set forth in our SEC filings actual results might differ materially from any forward looking statements that we make today.
Christina James: These forward looking statements speak only as of the date that they are made we do not assume any obligation to update. These forward looking statements as a result of new information future events or other developments.
Speaker Change: This call will include a discussion of non-GAAP measures a reconciliation of these non-GAAP measures can be found in the press release and in the supplemental disclosure package on our Investor Relations website with that I will now turn the call over to Michael.
Michael Stubblefield: Thank you CJ and good morning, everyone. I appreciate you joining us today I'm starting on slide three.
Michael Stubblefield: We delivered another solid quarter with in line performance across all key financial metrics.
Michael Stubblefield: Reported revenue increased sequentially to $1 seven 1 billion.
Michael Stubblefield: Organic revenue declined <unk>, 7% year over year.
Michael Stubblefield: We were encouraged by another quarter of outperformance in bio processing.
Michael Stubblefield: <unk> order rates continue.
Michael Stubblefield: As well as sequential and year over year growth in our laboratory solutions segment.
Michael Stubblefield: Adjusted EBITDA margin was 17, 6% and adjusted EPS increased to 26 cents in the quarter.
Sequential mix headwinds were largely offset by strong realization of savings from our cost transformation initiative.
Michael Stubblefield: Our disciplined approach to working capital drove another quarter of best in class free cash flow conversion.
This enabled us to pay down over $200 million of debt, bringing our net leverage down to three eight times.
Michael Stubblefield: Given our strong year to date performance, we are raising our free cash flow guidance for the year.
Michael Stubblefield: On October 17, we successfully closed the previously announced divestiture of our clinical services assets, which provided support for customers engaged in clinical trial activities with kidding bio repository and archiving services.
Michael Stubblefield: This divestiture allows us to focus on our lab and production platforms, where we have strategically advantaged position and scale higher growth entitlements and lower capital investment needs.
Michael Stubblefield: After a highly competitive process, we are confident we receive full value for the business.
Michael Stubblefield: The $500 million in after tax proceeds combined with our strong cash generation accelerates our path to achieving adjusted net leverage of less than three times.
Michael Stubblefield: In addition to our strong operating results. This quarter. We also made considerable progress in advancing our long term growth strategy.
Michael Stubblefield: Recent highlights include the.
Michael Stubblefield: The expansion of our magnetic mixing systems portfolio with the introduction of a new tabletop mixer.
Michael Stubblefield: We launched this new product at the recent Bioprocess International Conference in Boston, where we showcased our integration capabilities with multiple scientific and keynote presentations.
Michael Stubblefield: And our lab segment, we launched several new third party branded products, including adjuvant advanced analytical instruments for advanced battery and sustainable energy applications sorry.
Michael Stubblefield: <unk> life Science, and blood collection consumables as their first major U S distribution partner.
Michael Stubblefield: And Oxford, Nana <unk> grid ion long read NGF sequencer further expanding our collaboration with <unk> to bring this higher throughput instrument to market in Europe and the Americas.
Michael Stubblefield: We officially opened our new flagship innovation center in Bridgewater, New Jersey.
Michael Stubblefield: This 60000 square foot facility staffed with Phd scientists Biopharma engineers biologists and bio engineers is one of 13 of onshore innovation centers globally dedicated to solving life Sciences biggest challenges.
The Bridgewater innovation center includes capabilities for upstream and downstream process development pilot plant for scale up stimulations, and analytical and bioanalytical labs that support multiple modalities, including monoclonal antibodies and cell and gene therapies and protein peptide therapeutics.
Our <unk> business received an award from the prestigious <unk> Institute for excellence and process improvement and quality management.
Michael Stubblefield: I recently had the opportunity to visit this team in California, and witnessed firsthand how their commitment to the onshore business system is driving tangible operational results and fostering strong employee engagement consistent with our culture of continuous improvement.
Michael Stubblefield: We continue to improve the efficiency and productivity of our supply chain operations.
Michael Stubblefield: In the quarter, we completed major technology installations at our Brasilia, California site and opened a new facility in Devens, Massachusetts to support our fluid handling business we.
Michael Stubblefield: We advanced our sustainability platform and recently received an updated rating from <unk>, a global leader in business sustainability assessments that places of onshore in the top 17% of over 130000 rated companies globally.
Michael Stubblefield: Additionally, we signed our first virtual power purchase agreement through the energized program a pharmaceutical industry sponsored program that will reduce our energy costs and deliver renewable energy to our operations across Europe.
Michael Stubblefield: Finally, our team continues to effectively execute our multi year cost transformation initiative.
With several critical work streams ahead of schedule.
Michael Stubblefield: We are confident that we will exceed our in year cost savings target of $75 million in 2024.
Michael Stubblefield: Turning to our segment results laboratory solutions modestly outperformed our plan returning to growth for the first time in two years.
Michael Stubblefield: Within Biopharma overall market conditions remained relatively stable.
Michael Stubblefield: Year over year increases in biotech funding have not yet translated into increased preclinical spending and large pharma continue their pattern of cautious spending and prioritizing their clinical pipelines.
Michael Stubblefield: In our other end markets core diagnostic testing demand remains strong.
Michael Stubblefield: And we delivered growth in both our education and government and applied end markets underscoring the strength of our diversified platform.
Michael Stubblefield: Consumables and services performed well and equipment and instrumentation demand improved modestly from first half levels.
Michael Stubblefield: In Bioscience production bio processing end market conditions continue to improve production.
Michael Stubblefield: Production levels increased and this quarter. The FDA approved 13, additional biologics and protein peptide therapies for various indications, including oncology Alzheimers and ulcerative colitis.
Michael Stubblefield: In line with the strengthening conditions, our bio processing sales outperformed our expectations of a low single digit decline, finishing flat year over year.
Michael Stubblefield: Strong order momentum once again reinforces our confidence in mid to high single digit bottle processing growth in the fourth quarter.
Michael Stubblefield: Outside of bio processing, we saw sequential growth in biomaterials offset by declines in our advanced technology sales in the us.
Michael Stubblefield: In summary, we delivered another quarter of solid performance. Our cost transformation is ahead of plan and we have raised our free cash flow guidance for the year.
Order momentum in Bioprocess and continues and we are encouraged by the return to growth in our laboratory solutions segment.
Speaker Change: With that I'll now turn it over to Brent to walk you through our third quarter results in more detail.
Brent Jones: Thank you Michael and good morning, everyone I'm, starting with the numbers on slide four reported revenue was $1 seven $1 billion for the quarter declining 0.7% on an organic basis sales trends in our laboratory solutions segment were similar to second quarter levels.
Brent Jones: With a modest improvement in equipment and instrumentation demand within our Bioscience production segment Bioprocess, Inc. Outperformed expectations, while advanced technologies were modestly below plan.
Brent Jones: Adjusted gross profit for the quarter was $573 million and adjusted gross margin was 33, 4% adjusted gross margins declined sequentially largely due to mix key contributors were the increase in equipment and instrumentation lab solutions and headwinds in advanced technologies.
Brent Jones: In Bioscience production.
Brent Jones: Year over year, adjusted gross profit was impacted by mix and modestly lower sales volume.
Adjusted EBITDA was $303 million in.
Brent Jones: And adjusted EBITDA margin was 17, 6% our cost transformation initiative continues to drive meaningful SG&A savings nearly offsetting the sequential mix related headwinds to gross margins on a year over year basis performance was impacted primarily by our incentive compensation reset.
<unk>.
Brent Jones: Adjusted operating income was $275 million at a 16% margin in line with adjusted EBITDA performance and the drivers just noted.
Brent Jones: Adjusted earnings per share were <unk> 26 for the quarter, a one sequential and year over year improvement our adjusted EPS performance in the quarter reflects the flow through of our adjusted EBITDA result, as well as lower net interest expense interest expense favorability was driven by incremental debt paydown from output.
<unk> and free cash flow and the impact of our interest rate swap termination.
Speaker Change: As Michael noted, we delivered another strong quarter of free cash flow generating over $200 million in the quarter and approximately $550 million year to date inclusive of cash costs related to achieving our transformation savings.
Speaker Change: Excluding those same costs, we have generated approximately $625 million of free cash flow in the first three quarters against our original full year guidance range of $600 million to $650 million.
Speaker Change: In Q3, we paid down over $200 million of debt and our adjusted net leverage ended the quarter at three eight times adjusted EBITDA.
Speaker Change: We closed on the sale of our clinical services assets on October 17th after accounting for transaction costs and expected tax payments, we netted approximately $500 million in cash proceeds, which we intend to use for debt paydown.
Speaker Change: As part of the transaction, we also transferred balance sheet capital lease obligations of approximately $50 million further reducing our leverage we now expect to finish the year at or below three four times adjusted net leverage and continue to make meaningful progress towards our target of sub three times.
Speaker Change: <unk> adjusted net leverage.
Speaker Change: Slide five outlines our segment performance Laboratory solutions revenue was $1 7 billion for the quarter and grew 0.6% versus prior year on an organic basis sequentially sales grew modestly due in part to an improvement in equipment and instrumentation.
Speaker Change: While biopharma and healthcare continue to be pressured by the cautious spending environment. We saw nice improvements in other parts of the portfolio education and government grew mid single digits year over year, and our applied and industrial sales grew again with growth in both the Americas and Europe.
Speaker Change: Adjusted operating income for laboratory solutions was $152 million for the quarter with a 12, 9% margin.
Speaker Change: Sequentially Laboratory solutions adjusted operating income was up modestly we had a slightly negative mix at the gross margin line, largely offset by spend controls and transformation related SG&A savings.
Speaker Change: Adjusted operating income margin decreased 20 basis points from Q2.
Speaker Change: The year over year adjusted operating income decline was driven by the impact of our annual incentive compensation reset partially offset by savings from our cost transformation initiative.
Speaker Change: Bioscience production revenue was $543 million an organic.
Speaker Change: Decline of approximately three 5% versus prior year sequentially reported revenue declined modestly primarily due to advanced technologies.
Speaker Change: Bio processing, representing about two thirds of the segment outperformed expectation and was roughly flat year over year with another strong quarter of order intake biomaterials performed in line, while advanced technologies was somewhat below expectations.
Speaker Change: Adjusted operating income for Bioscience production was $138 million for the quarter, representing a 25, 4% margin on a sequential basis. Adjusted operating income margin was impacted by mix and higher freight expense year over year adjusted operating income declines were largely driven.
Speaker Change: By incentive compensation headwinds.
Speaker Change: Moving to the next slide.
Speaker Change: We are reiterating our full year P&L guidance net of the impact of our clinical services divestiture and raising our free cash flow guidance.
Speaker Change: Clinical services was expected to generate approximately $200 million of annual revenue, which will no longer be in our results as of October 17th Accordingly, we are adjusting our reported revenue guidance for the year by approximately $50 million to reflect this impact.
Speaker Change: Clinical services was part of our lab solutions segment. So these expectations should likewise be adjusted.
Speaker Change: The divestiture is approximately 10 basis points dilutive to our full year adjusted EBITDA margin and <unk> dilutive to adjusted EPS. As a result, we now expect adjusted EBITDA margin of 17, 3% to 17, 8% and adjusted EPS of <unk> 95 to one.
Speaker Change: Dollars three for the full year.
Speaker Change: Given our strong free cash flow performance. This year, we are raising our free cash flow expectation from the original range of $600 million to $650 million to more than $750 million. This.
Speaker Change: This is before transformation related cash costs of approximately $100 million.
Speaker Change: A couple of final comments on organic growth, we are reiterating our expected full year organic growth of negative 2% to positive 1% as our organic growth assumptions remain unchanged. The midpoint of our guidance assumes an approximately 49%, 51% first half to second half.
Speaker Change: <unk> revenue split as we have anticipated all year, the low end of the range assumes a more muted seasonal pattern by.
Speaker Change: By segment, we expect laboratory solutions organic growth to be flat to modestly up in Q4, leading to an unchanged expectation of flat to low single digit declines for the full year, we expect bioscience production organic growth of low to mid single digits in Q4 with strong order growth supporting.
Speaker Change: Mid to high single digit organic growth in bio processing for the full year, we expect bioscience production and bio processing both to decline low single digits organically also unchanged.
Speaker Change: I'll now turn the call back to Michael.
Michael Stubblefield: Thank you Brian before we conclude I would like to summarize the key takeaways from another strong quarter.
Michael Stubblefield: We are encouraged to see our ongoing commercial intensity driving growth in our lab business alongside continued outperformance in bio processing.
Our order book continues to grow positioning.
Michael Stubblefield: Positioning us for mid to high single digit bio processing growth in the fourth quarter.
Michael Stubblefield: Our cost transformation initiative is delivering results ahead of plan.
Michael Stubblefield: Allowing us to substantially offset the mix headwinds we experienced in the quarter.
Michael Stubblefield: We will exceed our in year savings target of $75 million and we'll exit the year with run rate savings of more than $150 million.
Michael Stubblefield: Enabled by the <unk> onto our business system, our disciplined approach to working capital resulted in another quarter of best in class free cash flow conversion and.
Michael Stubblefield: And we raised our free cash flow guidance for the year.
Michael Stubblefield: Together with the proceeds from our clinical services divestiture, our strong free cash flow is accelerating our deleveraging efforts and positively impacting our earnings.
Michael Stubblefield: We continued to make progress with our new operating model, realizing significant commercial and operational benefits just 10 months in.
Michael Stubblefield: We are now a leaner more agile and more efficient organization.
Michael Stubblefield: This new model is also enhancing both our internal processes and the way our customers experience our platform.
Michael Stubblefield: Importantly, we have significantly advanced our long term growth strategy, achieving key milestones in the areas of innovation, new product introductions sustainability and supply chain infrastructure.
I want to extend my gratitude to our onshore associates across the globe.
For their dedication to serving our customers and their invaluable contributions to our success.
Michael Stubblefield: I'll now turn it over to the operator to begin the question and answer portion of our call.
Michael Stubblefield: Thank you.
I would like to ask a question today. Please do so now by pressing star followed by the number one on your telephone keypad.
Speaker Change: If you change your mind or do you feel like Youre question has already been answered you can press star and then two with Julia Xu from Nicky.
Speaker Change: Our first question today comes from Dan Brennan with TD Cowen.
Speaker Change: Please go ahead Dan.
Dan Brennan: Great. Thanks, Scott Thanks for the question and thanks for the.
On the call.
Dan Brennan: Maybe just on the implied fourth quarter guide just to start guys.
Speaker Change: Some color right at the end on the segments, but could you just kind of give us a sense of.
Speaker Change: Where we should be thinking about overall for the company because if you took the full year guide.
Speaker Change: Zero to 12% is what's kind of implied in the fourth quarter. So wide. So just help us a little bit on that and then b just as it relates to bioscience production, Brad I think I heard you say low single to mid single if I can.
Speaker Change: Plug that in I think I come up with kind of down three for the year I think your prior guidance for the full year was not pointing to ask maybe just unpack a little bit of the overall guide and what it means for the segments for the fourth quarter.
Speaker Change: Yeah, absolutely. Thanks for the question Dan.
<unk>.
Speaker Change: I wouldn't I wouldn't read much into the broad guidance point here other than we were we're really updating for the impact of the clinical services divestiture there.
Speaker Change: Now on.
Speaker Change: The really the outlook broadly unchanged there in terms of what we see in the segments I think the important point is returned to growth in web solutions there.
Speaker Change: To up a little bit in Q4.
Speaker Change: The mid to high <unk> in the mid to high growth in Bioprocess in Q4, and then the few really unchanged and bps for the segment down low single digits. There in Q4.
Speaker Change: Okay.
Speaker Change: And then I'm sure we can impact that more on the call here, but and then maybe just as we turn the page I think some of your peers already.
Speaker Change: Earlier in the week gave some color on 25, whether explicitly or implicitly. So I think the street's at like four 5%.
Speaker Change: Mike you talked about a lot of optimism on cost cutting.
Speaker Change: Some of the initiatives you have but still a tough environment I mean does that seem like a realistic starting point do you think at this point from what Youre seeing in your business trends.
Speaker Change: Well, then I would say probably a couple of things firstly I think as <unk>.
We've done in previous years, where we sit here in the year is probably a little bit too early to comment on on 2025, we'll certainly see how Q4 plays out.
Speaker Change: And for our normal cadence.
Speaker Change: As we as we get into our our fourth quarter.
Speaker Change: Call for next year.
Speaker Change: Okay.
Speaker Change: Okay, great. Thank you.
Speaker Change: Our next question comes from Doug Schenkel with Wolfe Research. Please go ahead Doug.
Doug Schenkel: Hey, good morning, everybody. Thanks for taking the questions actually my first one.
Speaker Change: Let me.
Build off of Dan's question so.
Speaker Change: Dan second question so.
Speaker Change: As we think about Q4, EPS I think the midpoint of guidance implies something like 27% 28.
Speaker Change: Recognizing youre not going to guide for 'twenty five now that's not what I'm asking but.
Speaker Change: If we just kind of annualize that.
Speaker Change: For 2025, recognizing the world's gradually getting better your order book continues to improve.
Speaker Change: Your cost transformation initiatives continue to take hold.
Just annualizing the Q4 number be a good way to kind of establish a minimum number for next year, assuming things just continue to move in the direction. They are moving.
Speaker Change: Yes, Doug.
Couple of things, Firstly, certainly understand the math that youre, because youre trying to do but we're just reiterate for us it's probably a bit too early to comment on 2025.
Speaker Change: But what I would probably draw your attention to is what we've experienced this year.
Speaker Change: In our lab business, it's been a year of stability and somewhat gradual improvement.
Speaker Change: Certainly we're encouraged by the return to growth in the third quarter.
Speaker Change: As well as gradual recovery in the in the bio processing space, We've got a best in class platform.
Speaker Change: They're in.
Speaker Change: The outperformance for yet another quarter is encouraging I think we've got a good setup as we as we exit the year, but.
Speaker Change: Structurally our order book doesn't really give us the visibility to predict the timing or the shape of how things are going to play out next year, but I'd say the end market fundamentals are strong we're encouraged by momentum in our business, especially bio processing and perhaps most importantly, I think we're doing all the right things to ensure we were well.
Speaker Change: Positioned to capitalize.
Speaker Change: On the growth.
Speaker Change: Presents itself next year.
Speaker Change: Alright, Thanks, Michael Cant blame me for trying to and hopefully.
Speaker Change: Alright, and then I just wanted to follow up on up with an unrelated question on bps. So on the whole bps came in I think a little bit of light of expectations, but bio processing was actually better than expected, which I think leads us to the conclusion that maybe.
Speaker Change: That was new so.
Speaker Change: Can you just give us some color on what's going on there and then I guess higher level for this segment I think margin was a smidge lower than the margin you generated in that segment in the second quarter on similar revenue I'm. Just wondering if that was mix or something else like maybe you pulled forward some investment in the quarter or something like that.
Speaker Change: Yes, let me take your first one Brent can handle your question on margin Doug.
Speaker Change: On the bps segment.
Speaker Change: We have kind of a broad diversified platform there probably three principal components there.
Speaker Change: Two thirds of the platform as our bio processing platform again, another quarter of outperformance we delivered.
Speaker Change: Kind of flat performance year over year, as well as sequentially compared to a low single digit decline.
Speaker Change: We're actually encouraged to see our biomaterials platform grow sequentially.
Sequentially. So another good quarter there so the pressure really in that segment was within our advanced technologies.
Speaker Change: Platform and primarily in.
Speaker Change: Hi.
Speaker Change: A down quarter on U S semiconductors.
Doug Schenkel: Hey, Doug on the on the margin side.
Speaker Change: Doug following there on the margin side I mean, there are a few things going on as sort of as we noted in the script there.
Speaker Change: We did have higher freight expense in that statement.
Speaker Change: Going on in the World There, we work very hard at that but that was a headwind to us and we also had.
Speaker Change: The specific comments to Michael we also had a bit of the mix of the mix there.
Speaker Change: Nice performance in bio processing there the headwinds in advanced technology, if you put that together with some mix of the mix and that leads to that performance.
Speaker Change: Got it alright, thanks, guys.
Speaker Change: The next question comes from Tycho Peterson with Jefferies.
Speaker Change: Please go ahead.
Hey, Thanks, guys.
Speaker Change: All of this I'm going to ask another question, you'll have to <unk> range Im just curious how you're guiding us to the midpoint and high end.
Speaker Change: Can you flesh that out a little bit and then the implied margin in <unk> was also a pretty wide.
Speaker Change: Wondering if you can kind of give us some of the gives and takes on the margins.
Speaker Change: Yes, Tycho. Thanks for the question look the broad view on the on the guidance. There is the midpoint of the guidance would get you to a seasonal ramp in the lab business. We talked about this some last quarter the low end would be more muted.
Muted conditions are sort of similar.
Speaker Change: To the exit rate we saw in Q3, there. So that's the reason for the broadband thats consistent with the environment that that we had talked about before the flow through the margin.
Speaker Change: Part of this we haven't wanted to touch every piece of the guidance around there I think you could think of nice consistent consistent performance. There. We think about what Q4 wants to be that'll have similarity to Q3 assuming.
Speaker Change: Assuming the expectations, we talked about there again in Q4, we talked about lab flat to modestly up.
Speaker Change: PPS positive low single digit to mid single digit there you put that all together the puts and takes with the headwinds of the clinical services divestiture, which is some headwind to margin.
Speaker Change: And then nice tailwind from the mid to high Bioprocess, there that gets you in a consistent.
Speaker Change: <unk> there too.
Speaker Change: Q3 on a margin basis.
Speaker Change: Okay. That's helpful and then.
Speaker Change: Going back to one of the questions earlier from Doug on some of the other businesses you flagged semi I'm just curious your outlook there how much pressure you think this could put out numbers going forward.
Speaker Change: And then also what are you thinking on Newfield going forward as well I know you don't want to comment on 25, but just curious on underlying trends there and how you have to think about what youre seeing.
Speaker Change: Yes, so a couple of things to unpack there for you Tycho firstly on.
The new salt platform.
Speaker Change: <unk> talked about this in a lot of different forums isn't really terrific.
Speaker Change: Platform extremely well positioned.
Speaker Change: The business is running a bit ahead of plan. This year again, we saw a sequential growth in.
Speaker Change: In Q3, which was encouraging we've got a great innovation pipeline.
Speaker Change: Procedure counts are trending in the right direction here. So I think the setup for that long term continues to be quite favorable.
Speaker Change: We.
Speaker Change: We would anticipate over the long term that being a mid to high single digit growth platform for us and certainly nothing ahead of us that would.
Speaker Change: Kate that's not that's not possible on the semi front that you referenced there certainly some some pressure building in that end market as we move through the.
Speaker Change: In the quarter.
Speaker Change: There are some bright spots in that space.
Speaker Change: About the tech where the technology is headed there, but what we saw in the quarter was.
Speaker Change: Install and the recovery, particularly in the U S.
Speaker Change: And a little bit of subtraction getting lost there in the end market you see that.
Speaker Change: Tycho in light of the recent public updates from from some of the key players in the.
Speaker Change: In this space.
I think you are baked into our outlook for the fourth quarter as we would anticipate that to continue Unfortunately.
Speaker Change: That's a relatively small part of the business and given the strength in bio processing and biomaterials.
To largely offset that weakness with strength in those other.
Speaker Change: Areas of our business.
Speaker Change: Okay. Thank you.
Speaker Change: The next question comes from Michael <unk> with Bank of America.
Speaker Change: Please go ahead.
Great. Thanks.
Michael <unk>: Thanks for taking my question guys I wanted to talk a little bit about the clinical services divestment and the impacts of the guide.
Speaker Change: You only really talked about.
Speaker Change: The last two five months of the quarter, but is it reasonable to just take that and pro rate that the fiscal year 'twenty five meaning what you said $200 million a year youre seeing 150 of it. This year. So do you expect the other $1 50 give or take next year and then in terms of EBITDA. It's a 10 bps dilution to the EBIT margin this year so.
30 to 40 bps impact to EBIT margin next year.
Speaker Change: Or is there any other seasonality, we should keep in mind or anything like that.
Michael really good.
Speaker Change: There certainly I think the amount that you've laid out there makes it makes a lot of sense just to reiterate a couple of other points here, we've talked about the business being roughly $200 million on an annualized basis theres not a lot of seasonality to that so you see roughly a quarter of that impact being taken in Q4 and.
Speaker Change: I think it would be safe for you to assume.
Speaker Change: That you would see a similar impact as what we're seeing here in Q4 play out through the first three quarters of.
Next year, not just for the top line, but all the way through the P&L.
Speaker Change: Okay, that's easy.
Speaker Change: And then the other point was you mentioned a couple of times during the call. The cost savings you're ahead of your $75 million target for the year.
Speaker Change: Is that a little bit of timing like some pull forward from next year is there you saw a little bit more what did shop.
Speaker Change: Are you potential for upside to that number for next year as well just how we think about.
Speaker Change: Dot comments in the context of this is a three year program.
Brent Jones: Hey, Michael it's Brent I'll take that.
Brent Jones: Look.
Brent Jones: Yes.
Brent Jones: We appreciate the focus on that year to date realization is nicely ahead of plan for the full year.
Michael Stubblefield: We still have hard work to do in Q4, but we expect to deliver comfortably in excess of $100 million in the year. This puts us nicely ahead of the $150 million exit rate that Michael noted on the call last quarter.
Speaker Change: Really how we got there was year to date year to date realization ahead of plan, we got more in year impact we started talking about that on the Q1 call due to being really quick execution in connection with that.
Speaker Change: I wouldn't read anymore into what it means for the broad program three years, the $300 million. We're obviously incentives to get these things done rapidly, but we'll update you with the guide there, but I would say it's.
Speaker Change: Better than steady she goes there.
Speaker Change: Yes.
Speaker Change: Okay. Thanks, a lot guys.
Speaker Change: Yes.
Speaker Change: The next question comes from Vijay Kumar with Evercore ISI.
Speaker Change: Please go ahead.
Hi, Michael Good morning, and thank you for taking my question.
Vijay Kumar: Just one back on that side of the performance in the quarter.
Vijay Kumar: When you look.
Vijay Kumar: Look at within BP ex bps I think.
Vijay Kumar: The other parts of the business was down mid teens.
Vijay Kumar: I know you mentioned semi was this the timing it was there some timing impact.
Vijay Kumar: <unk> share in.
Vijay Kumar: Should that come back I know you mentioned.
Vijay Kumar: Some of the peers, what's the Reeves.
Vijay Kumar: Looking at companies like ASML is that <unk>.
Vijay Kumar: How to think of semis.
Speaker Change: Yeah, a couple of things there Vijay thanks for the question.
Again, just to make sure it's crystal clear for the call today.
Speaker Change: <unk> processing continues to out outperform we did grow our biomaterials platform the neutral platform sequentially. So the pressure really here is within our.
Speaker Change: <unk> segment advanced technologies segment as it were.
Speaker Change: Primarily in the U S semiconductor sector, we provide formulated solutions that go directly into semi.
Speaker Change: Semiconductor manufacturing processes. So I think the read through to the end market you would probably best to look at.
Speaker Change: The manufacturers of semiconductor chips themselves.
Speaker Change: Not really timing related I think as I said the answer to one of the other questions.
Speaker Change: This has been an end market that had significant headwinds throughout all of last year, we had been on a pace of.
Speaker Change: Recovery as we've moved through the first half of this year and even into the early days of the third quarter and what we really saw as we moved through the third quarter was.
Got that momentum.
Stall out and we see a bit of a pause here in that recovery in our.
Speaker Change: Assumptions for the fourth quarter would contemplate that continuing based on the forecast we're getting from our customers.
Understood.
Speaker Change: I mean, you did bring up bioprocess.
Speaker Change: <unk>.
Speaker Change: I guess, the order trends gives visibility to mid to high singles.
Speaker Change: In Q4.
Speaker Change: Order trends.
Speaker Change: I'm getting to maybe something like a 2% organic for all companies.
Speaker Change: Based on your <unk> outlook for Q4 is that like a reasonable jump off point for next year.
Well, yeah, thanks for bringing it up.
A really important part of our story here, we are encouraged Vijay by the continued momentum that we see in our in our order book with another really strong.
Speaker Change: Quarter in that regard and I'd also say.
Speaker Change: Importantly, it's not just about the order book, but we're certainly seeing that order book translate into revenue.
Speaker Change: Which enabled another quarter of outperformance in bio processing and then based on the orders and momentum that we have I think we see a lot of confidence in our ability to deliver on mid to high single digit growth in bio processing within the fourth quarter.
Speaker Change: Our year to date revenue and order trends validate that we have a best in class platform.
Speaker Change: A sustained track record of share gains. So I think we like our positioning in the setup for for Q4 is strong and when we look against our long term algorithm still some room to go here in terms of getting that platform all the way back, but we really like the trajectory and certainly are encouraged Vijay.
Vijay Kumar: Understood. Thanks, guys.
Speaker Change: The next question comes from Dan Leonard with UBS.
Dan Leonard: Dan. Please go ahead.
Dan Leonard: Thank you and that 20% EBITDA margin exit rate for 2025 that target you have can you remind me what growth you would need to achieve that and as the clinical service services divestiture impact that target at all.
Dan Leonard: Yeah.
Speaker Change: Yes, great question.
Speaker Change: Dan when we look at that that target that we've set of a 20% exit rate for last year. What we are for next year excuse me. What we've said about that is we had a high conviction and we do have a high conviction in our ability to achieve that primarily based on the many different ways that we can get there, including the self help measures and the things that we can.
Speaker Change: Control <unk> given some color here on.
Speaker Change: How our cost transformation initiative is trending in that certainly gets you.
Most of the way there.
Speaker Change: And it doesn't imply a full recovery of the end markets and we don't need a lot of heroics on the on the top line to get there. So.
Speaker Change: You still got a lot of conviction about that the fact that we're ahead of plan on our cost transformation will certainly help.
Speaker Change: Now it is worth pointing out when we set that target we didn't contemplate the divestiture of our clinical services platform. So as we get into our planning for.
Speaker Change: For 2025, we are certainly going to have to take that into account, but our original assumptions I think are still very.
Speaker Change: Very much in play here and we can get get to that level adjusted for the clinical services divestiture with things that are primarily within our control.
Speaker Change: Understood and as a follow up Michael can you give your updated view on the competitive environment in lab solutions in the market share picture there.
Speaker Change: Yes, great question.
Speaker Change: Dan.
Michael Stubblefield: First we just reiterate how encouraged rewards to see our lab business returned to growth for the first time in a couple of years the activity levels. There have been improving and we finally were able to push that into the into growth territory.
Michael Stubblefield: The sustained commercial intensity that we've that we've referenced in a number of different forms over the last year or so.
I think is certainly correlated to the outperformance we're seeing in that in that segment and when I compare.
Our disclosures here around lab to other disclosures that others are making on lab.
Michael Stubblefield: I think you'll see a platform here that continues to outperform.
We're confident we certainly have.
Michael Stubblefield: Leading platform here and we remain focused on leveraging our capabilities to continue to grow share and I think there's certainly a lot of data points here to support our view here that we've got a nice share.
Michael Stubblefield: Story, particularly in things like academia and when you when you look at our performance in that end market in the in the quarter.
Michael Stubblefield: So.
Michael Stubblefield: It's a highly fragmented space, we're clearly a leader in.
Michael Stubblefield: We like our positioning and momentum here.
Speaker Change: Great. Thank you.
Speaker Change: The next question comes from Kevin Mcnamara with RBC capital markets.
Speaker Change: Please go ahead.
Kevin Mcnamara: Good morning, guys and thanks for taking the question appreciate it.
Kevin Mcnamara: First just on the implied guidance for Q4.
Kevin Mcnamara: Can you walk through that range of about $200 million based on your on your reiterated guidance can you just what do you need to see over the next couple of months for for you to hit the high end of that guidance or should investors really be focused on the midpoint of your guidance as I think about Q4 results.
Yeah Conor.
Kevin Mcnamara: Thanks for the point, which again go to my other comments on your we haven't wanted to overly tweak things here.
Kevin Mcnamara: The lower end assumes muted less seasonality really continuation of the exit rate out of Q3 to get to the midpoint there you'd see more of the seasonality that we discussed on our last call there.
Kevin Mcnamara: You need to see and I think another important point around that is we're really talking about the labs laboratory solutions piece of that there we have absolute high conviction on what we talked about for <unk> production as well as bio production, specifically, there and that just would be greater activity in the lab in that channel again.
Kevin Mcnamara: We like the exit rates were going to get to the mid or better you did.
Kevin Mcnamara: You would need to see an acceleration in activity there.
Speaker Change: Great. Thanks, and then on the cash flow generation really strong quarter. Congrats on that as we think about next year youre going to exit.
Kevin Mcnamara: At the year at three four.
Kevin Mcnamara: Times lever.
Is it realistic to think that you could start being active in M&A next year and what is the M&A environment look like right now.
Kevin Mcnamara: We.
Kevin Mcnamara: Okay, just on the accuracy.
Speaker Change: It is absolutely very likely during next year will be below three times net leverage there you just look at the cash generation as well as getting there on the on the EBITDA side of things that will put us in a position. There now we want is comfortably stay below our leverage target there so that as that adds complexity to that but I would say we will.
Speaker Change: In the position where to start looking at inorganic growth for some time next year, Michael I don't know if you want to supplement.
Michael: Yes, no I think thats exactly right.
Michael: Laser focused on deleveraging and getting ourselves in a position where we have.
Michael: Room under three times to be able to sustainably be a consolidator in this in this space and M&A remains an important part of our long term growth play.
Michael: Playback were not in our playbook, we're not in a hurry.
We'll see how it plays out next year, we will we've got a lot of things in flight here around our cost transformation in standing up our new segments.
Michael: We like the momentum in our end markets and our positioning.
Michael: Fortunately, we can create a lot of value with all the organic levers that we have available to us and whether its next year or future year will certainly get back to M&A at the appropriate time.
Speaker Change: Okay. Thanks for that.
Great.
The next question comes from Dan Arias with Stifel.
Speaker Change: Please go ahead Dan.
Dan Arias: Hi, Good morning, guys. Thanks, Mike at the Investor Day last year, you talked about the potential for an above average growth period. Once the recovery is underway and once orders sort of turned the quarter.
Dan Arias: Do you feel about that idea today when you look at the evolution of demand here in just the way that the dynamics are playing out as things slowly get better.
Dan Arias: Yes.
It's a really good question.
Dan Arias: And as.
Speaker Change: As we've talked about here today. Unfortunately, our business model doesn't give us the visibility to call the timing or the shape of how that does recover.
Speaker Change: But I just kind of point you to what we've experienced this year.
Speaker Change: Which is a year of stability gradual improvement in the lab.
Speaker Change: I'll be a little bit ahead of the curve on some of the applied markets in the academic space getting back to more normal rates.
Speaker Change: We still got some room to go here with activity levels in preclinical research.
Speaker Change: There are some some some things to like about that there are some certainly with a large pharma that are doing pretty well there and there are some green shoots.
Speaker Change: Even in the biotech space not across the board, but certainly some of the larger biotech.
Speaker Change: We see some of the step up in year over year funding starting to translate into.
Speaker Change: A step up in spend on that so we like we like that but there is still some headwinds there that we need to overcome.
Speaker Change: But the trajectory is encouraging when you flip over to the production side of the business our exit rate here of mid to high single digits.
Speaker Change: Certainly compared to where we've been this year is quite encouraging but against the long term algorithm that would have us in the double digit range. There is certainly room for improvement here.
Speaker Change: And we'll see how that that.
Speaker Change: That plays out.
Speaker Change: We've got high confidence in where things are going to go for Q4 based on.
Speaker Change: Our order book and the fundamentals are strong we've talked about that all year.
<unk> remains great.
Speaker Change: Great regulatory environment I think we have another 13 approvals in the in the quarter on new molecules for new therapies.
Speaker Change: And.
Speaker Change: The production rates are continuing to improve as the Destocking subsides. So I think the setup is good we'll see how.
Speaker Change: Q4, ultimately plays out and we'll build that into our plans for next year here, but probably a little bit too early to call.
How we see 25 coming out again.
Speaker Change: Okay. That's helpful. And then maybe just a follow up on the overall consumables piece I mean, it feels like the inventory drawdown phase that we've been talking about it as kind of run its course, but there is a level of restraint out there just overall on budgets. When you look ahead, a bit and I know youre not trying to raise expectations, we get people's hopes or anything but I'm curious.
Speaker Change: Thats just sort of conceptually when you think about the beginning of next year and <unk> consumables orders do you think they could have a bit of a catch up feel to them, maybe a little bit larger than normal if just spending into the end of the year was muted to a degree.
And now these companies are working with a fresh budget and maybe need to restock a bit does that seem plausible to you at all or just not really.
Yes, I am not exactly sure when you look at our consumables portfolio, which we which we benefit from that.
Speaker Change: Net.
Speaker Change: Inventories from our perspective, I think we would agree with your view that the <unk>.
Speaker Change: Stocking is pretty much behind us and for the most part.
Inventories have normalized and so we see our customers managing their inventories in line with their activity levels. So it feels like we have consumption.
Speaker Change: And demand matching the orders that were that we're seeing at the moment and certainly the activity levels continue to improve so I think that's that's encouraging on the flip side, we have about <unk>.
Speaker Change: 15% of our revenues or so.
Speaker Change: And the equipment and instruments side of things and that's probably been the bigger headwind.
Speaker Change: Across the space this year.
Speaker Change: Linked to budge.
Speaker Change: Budgets and capital spending and as you as we noted in our prepared remarks.
Speaker Change: Relative to where we're at in the first half of the year, we did see some sequential improvement in that as we got into the third quarter and that's somewhat reflected in our in our mix that we see this year in the quarter as well, but I think thats another good signal.
Speaker Change: The pipeline activity levels have been strong there all year, it's been taking longer to convert those pipelines to orders and revenue.
Speaker Change: But there was a bit of a turn up on that.
Speaker Change: Area in Q3, so you kind of step back from all of that things are definitely heading in the right direction.
Speaker Change: And the environment continues to improve.
Speaker Change: Yeah, Okay. Thank you.
Speaker Change: Okay.
Speaker Change: Your next question comes from Brian <unk> with Jpmorgan.
Please go ahead.
Speaker Change: Thanks. Good morning, Thank you for taking the question.
Brian: First off just on lab solution. So I know you guys don't want to guide to 2025 at this point, but just given the hyper focus that investors do you have a lab solutions into next year, how should we think about pricing in 2025 on the lab side of the portfolio and what could that mean in terms of a floor for what the lab segment. Thank you.
Brian: Given some of the budget pressures that we're seeing on pharma and biotech and the pressure on volume is there a world where lab.
Flat or declining next year, what does that pricing power I hope to find some of the performance and equate to some level of growth even if it's just on pricing.
Speaker Change: Yes, Rachel Thanks for the question and good morning.
Speaker Change: First a couple of things maybe on pricing for 2024, as we've said in a lot of different.
Speaker Change: Occasions pricing for us in the lineup is played out in line with our with our expectations, which means we've been able to.
Offsetting the Cogs inflation that we do see unfortunately, the environment on pricing and Cogs is largely normalized compared to where it's been over the last couple of years, where we've been having to take outsized price increases to the market. This year I think the dynamics have been.
Speaker Change: Closer to kind of pre Covid times, and we're right in the midst of that process, where we're working with our suppliers.
Speaker Change: To understand.
Cogs is going to look like.
Next year.
Speaker Change: Early indications would seem that it's similar to what we were seeing.
Speaker Change: This year, perhaps and we'll roll all that together and.
Speaker Change: <unk>.
Speaker Change: Come forward with our pricing strategy here for next year here in the next 30 60 days something like that.
Speaker Change: And there is nothing that we see here that you would give us.
Speaker Change: Pause for concern that we're not going to be able to drive our normal pricing relative to the Cogs environment into the end of the market teams.
Speaker Change: <unk> got a great process.
Speaker Change: Great discipline around this.
Speaker Change: I think.
As long as we're in line with that Cogs.
Speaker Change: I don't have any concerns at this point on that topic.
Speaker Change: Got it that's helpful. And then just on the Bioscience Protection segment Advanced technologies dynamics can you just breakdown for us what percent of the Bioscience production segment is exposed to silicon and biomaterials versus advanced technologies, and then within that advanced technology for total Kyle that grew mid single digits this quarter.
Speaker Change: I know Theres, a fair amount of exposure within the lab segment. So what did advanced technology deal within Bioscience production segment. This quarter, given the weakness you've been calling out on Sunday.
Speaker Change: Yeah. So just maybe to recast what we've said about the segment two thirds is bio processing I think we've covered performance of that pretty well here today, and then the balance of that 30% to 35% of the platform is.
Speaker Change: Between our.
Speaker Change: Our <unk> platform, our biomaterials platform and.
Speaker Change: The other applications and things like aerospace and defense and <unk>.
Speaker Change: Semiconductors.
Speaker Change: Overall at the enterprise level, we've talked about semiconductors being.
Speaker Change: Roughly.
Speaker Change: A couple of points of our of our overall.
Exposure.
Speaker Change: And you're right to note there is certainly some.
Speaker Change: Applied exposure in the in the lab.
Speaker Change: Where we actually saw growth in that part of the business and in the quarter, which is I think you just.
Speaker Change: A great proof point of not only the diversity of our platform, but certainly the resilience and relevance of our of our platform. So.
Speaker Change: The weakness that we saw there really was isolated to the semi.
Speaker Change: Activities in principally in the U S.
Speaker Change: <unk> is where we saw the.
Speaker Change: Kind of the headwinds materialize as we as we move through the quarter.
Speaker Change: Yes.
The next question comes from <unk> <unk> with Barclays.
Speaker Change: Please go ahead Lee.
Speaker Change: Great. Good morning, Thanks for the questions I just wanted to get a clarification up here on on Docs earlier question.
Speaker Change: So with the Biosciences exited at a low single digit to mid singles in <unk> and you guys are still talking about doing the bio production exit of mid to high I guess, as we think and I know everybody's trying to figure out 25.
Speaker Change: Five reduction actually a mid to high wooden why would that not be kind of the growth rate in 'twenty five.
It sounded like at the interpretation there was that it could be a little bit lower I'm, just trying to figure that out.
Speaker Change: Yes, I wouldn't I wouldn't try to extrapolate.
Our Q4 exit rates into whatever you think we're going to come forward with next year I think it's a good data point to show the trajectory of the <unk>.
Speaker Change: Coverage that we've experienced this year, starting the year down.
Speaker Change: Low teens.
Progressing to kind of flat here in the third quarter to now exiting at mid <unk> mid to high single digits. So I think we're on a great course here for.
Speaker Change: For bio processing overall, a lot of momentum in and where we're going and as I said before we're not yet back to our double digit growth rate there. So there's a bit more.
Speaker Change: Rooms.
Speaker Change: When you then look at.
Speaker Change: The biomaterials.
<unk>.
Speaker Change: We've outperformed this year relative to our expectations. There was a we grew that platform over 20% last year. So we knew this year was going to be.
Speaker Change: A little bit more challenged as a lot of inventory restock.
Speaker Change: A restocking that we experienced last year was going to be a headwind for us this year, but we like the fundamentals there.
Speaker Change: Dissipate a mid to high single digit growth rate for that platform over the over the longer term and we'll see where the semi.
Speaker Change: <unk> lands.
Speaker Change: Lands, but no.
Speaker Change: The exit rates for.
Speaker Change: For bio processing I think are constructive way to think about the jumping off point and we'll have to.
Speaker Change: Synthesize that through.
Speaker Change: Our process here as we come out with our with our full year guidance, but we like the setup. There. The pipelines are strong order book momentum continues now for <unk>.
Speaker Change: The last four quarters at least and so the.
Speaker Change: I think theres a lot to like about that movement.
Speaker Change: Yeah, Okay, I just wanted to clarify okay that makes sense.
Speaker Change: And then I just wanted to tease out a little bit here on the equipment drag on the margins I know you said it improved sequentially, but.
Speaker Change: <unk>.
Speaker Change: The Eni piece of the business has been soft across all peers in from every channel checks, so talk a little bit about what youre seeing there like what the what was the pick up.
Speaker Change: Was it still down year over year just.
Speaker Change: What was the ultimate drag on that margin and ultimately the outlook for the Eni coming back.
Speaker Change: Yes, a couple of things there youre right first of all and that it is a relatively modest part of the business, it's roughly 15% of the total.
Speaker Change: With a little bit more of that exposure in lab solutions, where we see roughly 20% of our lab revenues are linked to equipment and instruments.
Speaker Change: Market conditions generally speaking have been pretty similar all year really highlighted by this more cautious spending on capital items, particularly within.
Speaker Change: Biopharma.
Speaker Change: We did see some improvement as we've noted in the third quarter.
Speaker Change: It was up low single digits.
Speaker Change: Sequentially, but to your point, it's still down.
Year over year, I think the first half of the year, we were probably down high single digits low double digit kind of range and so.
Speaker Change: It did improve to.
Speaker Change: <unk>.
Speaker Change: Mid single digits in the in the in the quarter.
Speaker Change: Still a bit of a headwind, but as we've said actually the activity levels and pipelines have been pretty.
Speaker Change: Pretty strong most of the year all year.
What we see though is just.
Speaker Change: Our longer cycle time to get that activity converted to an order and ultimately realized in the P&L. So maybe some green shoots here in the quarter as things seem to be start moving in the right direction.
Speaker Change: Great. Thanks.
Speaker Change: Great.
Speaker Change: Yeah.
Your next question comes from Steven <unk> with Morgan Stanley.
Speaker Change: Please go ahead.
Speaker Change: Hey, guys. Good morning, I appreciate the dialogue.
Steven: Michael I, just wanted to double click on mid cap biotech a little bit I know like low single digit exposure for you, but what are you hearing from that specific customer constituency and given the weakness called out.
Speaker Change: Some of the <unk> and so on.
When do you think the rate cuts start to filter through in terms of customer psychology, or do you expect perhaps like election outcome Saturday to move things along a little bit on that front.
Michael Stubblefield: Great question Tejas, I'd say, a couple of things about the biotech space, it's a relatively modest exposure for us, but it is an important customer set just given the signs that they are that they are developing.
Speaker Change: And similar to what we're seeing with some of the large pharma, it's a little bit of a mixed bag here in that.
Speaker Change: Yeah, particularly a lot of the smaller biotechs still struggling under the weight of the funding headwinds that have been in play over the last couple of years.
Speaker Change: But we are starting to see some green shoots in this area.
Speaker Change: And if I kind of segment.
Speaker Change: Exposure here to the biotech space, we actually see some of the larger customers.
Speaker Change: Within that.
Speaker Change: Area to have a bit more access to cash maybe benefiting from some of the early <unk>.
Speaker Change: And funding on a year over year basis here, you're actually starting to return to growth. So still some headwinds that were not fully seeing all of the step up in funding translate into preclinical spend yet.
Speaker Change: But certainly we're encouraged by some of the green shoots that we are starting to see there.
Okay.
Speaker Change: Got it and then my follow up.
Speaker Change: Bill just on Europe, Michael just talk to us about sort of any signs of stress in the system are perhaps less sequential improvement, especially in important geographies like Germany.
You've got this dynamic of defense spending crowding out other priorities for some governments, but then on the other hand I think in the past you've also talked about how you're relatively under index to Biopharma there versus North America. So just paint a picture for us a little bit in terms of what youre seeing exiting the third quarter and into October here in Europe.
Speaker Change: Europe for us has actually been probably the strongest geography.
Speaker Change: As we as we look across the business I think even in the third quarter. It outperformed.
Speaker Change: The Americas and some of that I think can definitely be linked to.
What youre talking about there on maybe a little bit less exposure to preclinical research and biotech funding and such on a relative basis.
Speaker Change: When I look through to things like our applied exposure in the region.
Speaker Change: Actually saw some some pretty reasonable growth in the quarter for Europe, So Europe overall.
Speaker Change: Holding up quite well.
Speaker Change: Despite some of the macro factors out there and again I think it's just a great proof point of the benefits of a consumables driven portfolio and the resilience.
Speaker Change: Our platform offers.
Speaker Change: Got it appreciate that thanks, guys. Thanks.
Speaker Change: Thanks, David.
Speaker Change: We have time for one further question and so our final question today comes from Patrick Donnelly with Stifel.
Speaker Change #100: Patrick Please go ahead.
Hey, guys. Thanks for taking the questions.
Patrick Donnelly: Michael maybe just to follow up on that last one on the pharma piece.
Patrick Donnelly: Certainly heard from some folks that biotech continues to push things out a little bit.
Large pharma, maybe slightly better, but I guess when you guys think about that both customer bases are you seeing a bit of a dichotomy at all how are you kind of having conversations with customers.
Patrick Donnelly: Viewing the go forward in terms of the willingness to spend both into year end and then budgeting into next year as well.
Speaker Change #102: Yes, a couple of things to point out there.
Speaker Change #102: Patrick biotech funding has been a headwind going back to the early days of last year.
Speaker Change #102: We did see it tick up beginning in Q1 this year and as we sit here on a year to date basis. It is encouraging to note that overall biotech funding.
Speaker Change #102: Is up on a on a year over year basis, and we definitely see things heading in the right direction there, but it is it is somewhat mixed in terms of the picture out there as we talked to customers, particularly.
Speaker Change #102: The smaller biotechs, we definitely see more muted activity levels, you see fewer startups coming in that generally drive some good activity when funding is strong but the more established biotechs, Patrick we actually do see.
Speaker Change #102: The step up in funding translating that growth when I look into our.
Speaker Change #102: <unk> business.
Speaker Change #102: We saw that.
Speaker Change #102: A nice sequential improvement in that part of our.
Speaker Change #102: Business in the in the quarter.
We still do need some of the smaller folks to step up to.
Speaker Change #102: <unk>.
Speaker Change #102: You kind of get away from this being a generally a headwind, but there are some green shoots here that we have our eyes on that.
Speaker Change #102: Give us some some encouraging here and do align with this trend of funding being up year over year.
Speaker Change #103: That's helpful and maybe just the last quick one for Brent just on the gross margins in particular.
Speaker Change #103: Particular, I understand mix is obviously an impact this quarter just trying to think about the go forward, whether it's price mix and moving pieces, we should be thinking about at the right point.
Speaker Change #103: For 25, just taken this quarter.
I can move around a little bit with mix just trying to get our arms around that thank you guys.
Speaker Change #103: Yes.
Speaker Change #104: Yes look.
Speaker Change #105: You had another 25 there Patrick.
Speaker Change #105: We'll come back to you in February there, but I think I would just heavy focus Q4 and beyond we're going to have some headwinds from the clinical services divestiture.
Speaker Change #105: We do have the mixed variability you cited those headwinds should be.
Speaker Change #105: Essentially offset or more than offset by the growth in bioprocess and Q4, that's the real virtue of that mid to high. So I would think about Q4 is something were similar to Q3, and we will update you on all of the mix and everything else for the guide for 'twenty five.
Speaker Change #106: Understood. Thank you guys.
Speaker Change #106: Thanks.
Speaker Change #106: Okay.
Speaker Change #106: Okay.
Speaker Change #106: Okay.
Speaker Change #106: Okay.
Speaker Change #107: Thanks for all the questions. We have time for today and so I will turn the call back to the management team for any closing remarks.
Speaker Change #108: Yes. Thank you operator, and thank you all for joining us today.
Speaker Change #109: I appreciate your support of our business and really look forward to updating you when we get a chance to meet and until then be well everyone have a great Friday.
Speaker Change #110: Thank you everyone for joining us today. This concludes I'll call and you may now disconnect your lines.
Speaker Change #110: [music].
Speaker Change #110: Yes.
Yes.
Speaker Change #110: Okay.
Speaker Change #110: Yeah.